Oral dimethyl fumarate in children with multiple sclerosis: a dual-center study
N Makhani, T Schreiner - Pediatric Neurology, 2016 - Elsevier
Background First-line injectable therapies for multiple sclerosis in children may be
ineffective or not well-tolerated. There is therefore an urgent need to explore oral
medications for pediatric multiple sclerosis. We review our dual-center experience with oral
dimethyl fumarate. Methods This study was a retrospective review of children 18 years of
age or less with multiple sclerosisátreated with dimethyl fumarate at Yale University and the
University of Colorado. Clinical, demographic, and magnetic resonance imaging parameters …
ineffective or not well-tolerated. There is therefore an urgent need to explore oral
medications for pediatric multiple sclerosis. We review our dual-center experience with oral
dimethyl fumarate. Methods This study was a retrospective review of children 18 years of
age or less with multiple sclerosisátreated with dimethyl fumarate at Yale University and the
University of Colorado. Clinical, demographic, and magnetic resonance imaging parameters …
